ClinicalTrials.gg
Not yet recruitingNCT07846956Updated Sep 29, 2026

NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study

An observational study in Non-arteritic Anterior Ischemic Optic Neuropathy Obesity and Obesity, sponsored by Istanbul Saglik Bilimleri University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-29.

Sponsored by Istanbul Saglik Bilimleri University · Observational

How we know · 4 judgments

Updated Sep 29, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
28
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 353 studies in Obesity with a site in Turkey — 73 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.

Planned enrollment
145th of 160
28 · median 82
Started
2026
with 59 others
Observational
160 of 353
32 open now
Primary completion
2026-11
later than 40 of 89 live
Registered
336th of 353
by date

Among the 353 studies in Obesity with a site in Turkey, this one is the 145th largest by planned enrollment of the 160 observational ones that give a count, is one of 60 that started in 2026, is one of 160 observational ones, reaches primary completion later than 40 of the 89 other live ones, and was the 336th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

73 of the 353 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:

68 more — sign in →

All 73 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 353 studies in Obesity with a site in Turkey, or all of them as a file.
02

Study summary

Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists. Glucagon-like peptide-1 receptor agonists (GLP-1 RA), such as semaglutide and tirzepatide, are widely used for type 2 diabetes and obesity. Since 2023, case series, cohort studies and regulatory reviews have raised the possibility of an association between semaglutide and NAION, but published evidence is conflicting, and data in non-diabetic obese patients are limited.

This retrospective, single-center, descriptive real-world study will review the existing records of non-diabetic obese adults (BMI > 30) who used a GLP-1 RA and attended the ophthalmology outpatient clinic between January 2025 and February 2026 with at least two eye examinations. The aim is to describe the occurrence and time-related change of NAION and related ophthalmic findings in this population.

Read the detailed description

Background and rationale: NAION results from impaired perfusion of the optic nerve head, and risk is increased by type 2 diabetes, hypertension, sleep apnea and a small optic disc ("disc at risk"). Proposed mechanisms linking GLP-1 RA to NAION include rapid glycemic and weight change affecting optic nerve perfusion autoregulation, direct effects through GLP-1 receptors present in the retinal ganglion cell layer, and nocturnal hypotension. Studies that examine GLP-1 RA use and NAION together in non-diabetic obese patients were not identified in the literature review by the investigators.

Design: Retrospective descriptive study. Data will be collected by the investigators from the hospital information system; no new examination, parameter or intervention will be requested from patients. Data collection is planned from 30 May 2026 to 30 November 2026, after ethics committee and hospital approval.

Data collected: Age, education level, smoking, alcohol use, weight, height and BMI; ophthalmic findings including Snellen visual acuity, biomicroscopic anterior segment examination, intraocular pressure, fundus examination, direct/indirect light reflex, and retinal nerve fiber layer thickness measured by OCT. Data are recorded on a Descriptive Information Form developed by the investigators.

Sample size: Because no sampling will be performed, all patients meeting the criteria will be included. A power analysis using proportions of 0.38 and 0.09 from previous studies (95% confidence, alpha 0.05, 80% power) gave a required sample of 28 participants.

Statistical analysis: IBM SPSS 26.0. Descriptive statistics (number, percentage, mean, standard deviation); normality by Shapiro-Wilk test, skewness and kurtosis; t-test and/or Mann-Whitney U for two-group comparisons; ANOVA and/or Kruskal-Wallis H for three or more groups; correlation and/or chi-square analysis for associations. Significance level p \< 0.05 with 95% confidence interval.

Confidentiality: Personal information of patients will be kept confidential.

03

Conditions studied

  • Non-arteritic Anterior Ischemic Optic Neuropathy Obesity
  • Obesity

Keywords

  • NAION
  • GLP-1 receptor agonist
  • semaglutide
  • tirzepatide
  • obesity
  • non-diabetic
  • optic neuropathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Non-diabetic obese adults using a GLP-1 receptor agonist who attended the ophthalmology outpatient clinic of Kanuni Sultan Suleyman Training and Research Hospital between January 2025 and February 2026.

Eligibility criteria

Inclusion Criteria:

  • Age 18 years or older
  • Diagnosis of obesity ( > 30)
  • No hearing, speech or cognitive impairment
  • Not receiving treatment for major depressive disorder and not using antidepressant medication
  • At least two eye examinations with measurements on record
  • Verbal agreement to participate

Exclusion Criteria: • Diagnosis of diabetes

  • Diagnosis of hypertension
  • Previous optic neuritis or similar eye disease
  • Optic disc drusen, optic disc anomaly, glaucoma or other disease involving the optic nerve
  • High hyperopia or small, crowded optic disc
  • Not meeting the inclusion criteria or not willing to participate
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
28 participants (estimated)
Target follow-up
3 Months
Patient registry
Yes

Groups and cohorts

  • GLP-1 RA users (non-diabetic, obese)

    Adults aged 18 or older with BMI \> 30 and no diabetes diagnosis, who used a GLP-1 receptor agonist and had at least two ophthalmic examinations with measurements at the clinic between January 2025 and February 2026.

    Drug: GLP-1 Receptor Agonist Therapy

Interventions

  • DrugGLP-1 Receptor Agonist Therapy

    Use of a GLP-1 RA prescribed in routine clinical care. No study-specific treatment is given.

This study also gives SemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., TirzepatideStudies of TirzepatideTirzepatide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Occurrence of NAION

    Number and percentage of participants with a NAION diagnosis recorded in the ophthalmic examination records.

    Time frame: Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months

Secondary outcomes

  1. • Change in visual acuity (Snellen chart) between the first and last recorded examination

    Change in Snellen best-corrected visual acuity between the first and last recorded ophthalmic examination during the study period.

    Time frame: Baseline (GLP-1 RA initiation) to final recorded eye examination, up to 14 months

07

Study locations

1 site
08

References and documents

Publications

  • Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW Jr, Cestari D, Mallery R, Abbasi B, Bouffard M, Chwalisz BK, Estrela T, Rizzo JF 3rd. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. JAMA Ophthalmol. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthalmol.2024.2296. PubMed 38958939 ↗
  • Liu H, Zhang JT, Xin SH, Ren WN, Lu QK. Comprehensive review of glucagon-like peptide 1 receptor agonist treatment on the risk of cardiovascular outcomes and retinopathy as diabetic complications. Eur Rev Med Pharmacol Sci. 2023 Mar;27(6):2332-2340. doi: 10.26355/eurrev_202303_31768. PubMed 37013752 ↗
  • Kapoor I, Sarvepalli SM, D'Alessio D, Grewal DS, Hadziahmetovic M. GLP-1 receptor agonists and diabetic retinopathy: A meta-analysis of randomized clinical trials. Surv Ophthalmol. 2023 Nov-Dec;68(6):1071-1083. doi: 10.1016/j.survophthal.2023.07.002. Epub 2023 Jul 16. PubMed 37454782 ↗
  • Allan KC, Joo JH, Kim S, Shaia J, Kaelber DC, Singh R, Talcott KE, Rachitskaya AV. Glucagon-like Peptide-1 Receptor Agonist Impact on Chronic Ocular Disease Including Age-Related Macular Degeneration. Ophthalmology. 2025 Jul;132(7):748-757. doi: 10.1016/j.ophtha.2025.01.016. Epub 2025 Jan 23. PubMed 39863057 ↗
  • Aroda VR, Erhan U, Jelnes P, Meier JJ, Abildlund MT, Pratley R, Vilsboll T, Husain M. Safety and tolerability of semaglutide across the SUSTAIN and PIONEER phase IIIa clinical trial programmes. Diabetes Obes Metab. 2023 May;25(5):1385-1397. doi: 10.1111/dom.14990. Epub 2023 Feb 21. PubMed 36700417 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Nov 2026, 2 months later.

Of 796 non-industry observational studies under Obesity, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 106. This study's planned 2 months is below that.

Counting every sponsor, half of 842 studies reached it within 39 months; a quarter within 17 and three quarters within 96.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2026
First posted
Sep 29, 2026
StartEst.
Sep 21, 2026
Primary completionEst.
Nov 30, 2026
CompletionEst.
Nov 30, 2026
Last update
Sep 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 29, 2026
Show all 1 update
  1. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07846956
Lead sponsor
Istanbul Saglik Bilimleri University
Responsible party
GÜLDEN ANATACA (MsD,RN, Istanbul Saglik Bilimleri University) — Principal investigator
First posted
Sep 29, 2026
Start date
Sep 21, 2026 (estimated)
Primary completion
Nov 30, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Sep 29, 2026

Study contacts

GÜLDEN ANATACA
Contact
ganataca@yahoo.com
05059284244

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion